Therefore, several studies propose CD25 as a more sensitive and specific immunophenotypic biomarker of all forms of SM compared to CD2, with a specificity of 99.2% and a sensitivity of 100% [86]. This evidence concerns the gene CD2 and systemic mastocytosis.